[Federal Register Volume 59, Number 178 (Thursday, September 15, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-22866]
[[Page Unknown]]
[Federal Register: September 15, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Controlled Substances: Established Revised 1994 Aggregate
Production Quotas
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of final revised aggregate production quotas for 1994.
-----------------------------------------------------------------------
SUMMARY: This interim rule (59 FR 36784, July 19, 1994) which
established 1994 revised aggregate production quotas for some
controlled substances in Schedules I and II, as required under the
Controlled Substances Act (CSA) (21 USC 826), is adopted without
change.
EFFECTIVE DATE: This order is effective upon September 15, 1994.
FOR FURTHER INFORMATION CONTACT:
Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug
Enforcement Administration, Washington, D.C. 20537, Telephone: (202)
307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act
(21 U.S.C. 826) requires the Attorney General to establish aggregate
production quotas for controlled substances in Schedules I and II each
year. This responsibility has been delegated to the Administrator of
the DEA pursuant to section 0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn, has redelegated this function
to the Deputy Administrator pursuant to 59 FR 23637 (May 6, 1994).
On July 19, 1994, an interim rule establishing revised 1994
aggregate production quotas for certain controlled substances in
Schedules I and II was published in the Federal Register (59 FR 36784).
All interested persons were invited to comment on or object to these
proposed aggregate production quotas on or before August 18, 1994. No
comments or objections were received. The interim rule is adopted
without change.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866. This action has been analyzed in accordance with
the principles and criteria contained in Executive Order 12612, and it
has been determined that this matter does not have sufficient
federalism implications to warrant the preparation of a Federalism
Assessment.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq.
The establishment of annual aggregate production quotas for Schedules I
and II controlled substances is mandated by law and by international
treaty obligations. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
Therefore, under the authority vested in the Attorney General by
Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826),
delegated to the Administrator of the DEA by section 0.100 of Title 28
of the Code of Federal Regulations, and redelegated to the Deputy
Administrator, pursuant to 59 FR 23637 (May 6, 1994), the Deputy
Administrator hereby orders that the 1994 revised aggregate production
quotas, expressed in grams of anhydrous base, be established as
follows:
------------------------------------------------------------------------
Established
revised
Basic class 1994 quotas
(in grams)
------------------------------------------------------------------------
Schedule I:
Cathinone................................................ 4
3,4-Methylenedioxymethamphetamine........................ 14
Schedule II:
Dextropropoxyphene....................................... 123,398,000
Hydrocodone.............................................. 8,344,000
Hydromorphone............................................ 407,000
Noroxymorphone (for conversion).......................... 1,781,000
Phenylacetone (for conversion)........................... 3,352,000
------------------------------------------------------------------------
Dated: September 9, 1994.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 94-22866 Filed 9-14-94; 8:45 am]
BILLING CODE 4410-09-M
